Company / Cash & Equivalents
USANA HEALTH SCIENCES INC Cash & Equivalents History
FY2014-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$158.4M
FY2025
5-year range
$158.4M / $330.4M
FY2021-FY2025
Trend
-52.1%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents has fluctuated over the past 10 years, ranging from $71M in FY2014 to $330M in FY2023.
Based on SEC 10-K filings.
$158M in FY2025 with a 10-year CAGR of +1.4%.
Declined from $240M to $158M over the past 3 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -12.9%
- 5-Year CAGR
- -7.6%
- 10-Year CAGR
- +1.4%
Key checks
Key Insights
- 5-year CAGR of -7.6%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 52.1% year-over-year.
- Peak cash & equivalents was recorded in FY2023.
- Lowest cash & equivalents in the period was in FY2014.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $158.4M | -52.1% |
| FY2023 | $330.4M | +37.8% |
| FY2022 | $239.8M | +2.1% |
| FY2020 | $234.8M | +9.6% |
| FY2019 | $214.3M | -13.3% |
| FY2018 | $247.1M | +40.6% |
| FY2017 | $175.8M | +58.2% |
| FY2016 | $111.1M | -19.1% |
| FY2015 | $137.3M | +93.9% |
| FY2014 | $70.8M | +192.5% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026